Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

Francesca Ceccherini-Silberstein; Isabelle Malet; Lavinia Fabeni; Salvatore Dimonte; Valentina Svicher; Roberta D'Arrigo; Anna Artese; Giosuè Costa; Sara Bono; Stefano Alcaro; Antonella d'Arminio Monforte; Christine Katlama; Vincent Calvez; Andrea Antinori; Anne Genevieve Marcelin; Carlo Federico Perno

doi:10.1093/jac/dkq326

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

Francesca Ceccherini-Silberstein, Isabelle Malet, Lavinia Fabeni, Salvatore Dimonte, Valentina Svicher, Roberta D'Arrigo, Anna Artese, Giosuè Costa, Sara Bono, Stefano Alcaro, Antonella d'Arminio Monforte, Christine Katlama, Vincent Calvez, Andrea Antinori, Anne Genevieve Marcelin, Carlo Federico Perno

Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive). Methods: Gene sequences of the integrase (IN) and reverse transcriptase (RT) obtained from plasma samples of a well-defined cohort of 448 HIV-1-infected individuals (134 drug naive and 314 antiretroviral treated) were analysed. Docking simulations, using RT and IN models, were also performed. Results: Primary mutations and the majority of secondary mutations for raltegravir or elvitegravir were completely absent (or rarely found,

Original language	English
Article number	dkq326
Pages (from-to)	2305-2318
Number of pages	14
Journal	Journal of Antimicrobial Chemotherapy
Volume	65
Issue number	11
DOIs	https://doi.org/10.1093/jac/dkq326
Publication status	Published - Sep 3 2010

Keywords

Antiretroviral therapy
Co-evolution
HIV drug resistance
Integrase
Molecular docking
Polymorphisms
Reverse transcriptase

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1093/jac/dkq326

Cite this

Ceccherini-Silberstein, F., Malet, I., Fabeni, L., Dimonte, S., Svicher, V., D'Arrigo, R., Artese, A., Costa, G., Bono, S., Alcaro, S., d'Arminio Monforte, A., Katlama, C., Calvez, V., Antinori, A., Marcelin, A. G., & Perno, C. F. (2010). Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. Journal of Antimicrobial Chemotherapy, 65(11), 2305-2318. [dkq326]. https://doi.org/10.1093/jac/dkq326

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. / Ceccherini-Silberstein, Francesca; Malet, Isabelle; Fabeni, Lavinia et al.

In: Journal of Antimicrobial Chemotherapy, Vol. 65, No. 11, dkq326, 03.09.2010, p. 2305-2318.

Research output: Contribution to journal › Article › peer-review

Ceccherini-Silberstein, F, Malet, I, Fabeni, L, Dimonte, S, Svicher, V, D'Arrigo, R, Artese, A, Costa, G, Bono, S, Alcaro, S, d'Arminio Monforte, A, Katlama, C, Calvez, V, Antinori, A, Marcelin, AG & Perno, CF 2010, 'Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors', Journal of Antimicrobial Chemotherapy, vol. 65, no. 11, dkq326, pp. 2305-2318. https://doi.org/10.1093/jac/dkq326

@article{f23cd4541f2a4f88bd361da0845c7866,

title = "Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors",

abstract = "Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive). Methods: Gene sequences of the integrase (IN) and reverse transcriptase (RT) obtained from plasma samples of a well-defined cohort of 448 HIV-1-infected individuals (134 drug naive and 314 antiretroviral treated) were analysed. Docking simulations, using RT and IN models, were also performed. Results: Primary mutations and the majority of secondary mutations for raltegravir or elvitegravir were completely absent (or rarely found, ",

keywords = "Antiretroviral therapy, Co-evolution, HIV drug resistance, Integrase, Molecular docking, Polymorphisms, Reverse transcriptase",

author = "Francesca Ceccherini-Silberstein and Isabelle Malet and Lavinia Fabeni and Salvatore Dimonte and Valentina Svicher and Roberta D'Arrigo and Anna Artese and Giosu{\`e} Costa and Sara Bono and Stefano Alcaro and {d'Arminio Monforte}, Antonella and Christine Katlama and Vincent Calvez and Andrea Antinori and Marcelin, {Anne Genevieve} and Perno, {Carlo Federico}",

year = "2010",

month = sep,

day = "3",

doi = "10.1093/jac/dkq326",

language = "English",

volume = "65",

pages = "2305--2318",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

AU - Ceccherini-Silberstein, Francesca

AU - Malet, Isabelle

AU - Fabeni, Lavinia

AU - Dimonte, Salvatore

AU - Svicher, Valentina

AU - D'Arrigo, Roberta

AU - Artese, Anna

AU - Costa, Giosuè

AU - Bono, Sara

AU - Alcaro, Stefano

AU - d'Arminio Monforte, Antonella

AU - Katlama, Christine

AU - Calvez, Vincent

AU - Antinori, Andrea

AU - Marcelin, Anne Genevieve

AU - Perno, Carlo Federico

PY - 2010/9/3

Y1 - 2010/9/3

N2 - Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive). Methods: Gene sequences of the integrase (IN) and reverse transcriptase (RT) obtained from plasma samples of a well-defined cohort of 448 HIV-1-infected individuals (134 drug naive and 314 antiretroviral treated) were analysed. Docking simulations, using RT and IN models, were also performed. Results: Primary mutations and the majority of secondary mutations for raltegravir or elvitegravir were completely absent (or rarely found,

AB - Objectives: To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive). Methods: Gene sequences of the integrase (IN) and reverse transcriptase (RT) obtained from plasma samples of a well-defined cohort of 448 HIV-1-infected individuals (134 drug naive and 314 antiretroviral treated) were analysed. Docking simulations, using RT and IN models, were also performed. Results: Primary mutations and the majority of secondary mutations for raltegravir or elvitegravir were completely absent (or rarely found,

KW - Antiretroviral therapy

KW - Co-evolution

KW - HIV drug resistance

KW - Integrase

KW - Molecular docking

KW - Polymorphisms

KW - Reverse transcriptase

UR - http://www.scopus.com/inward/record.url?scp=77957875432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957875432&partnerID=8YFLogxK

U2 - 10.1093/jac/dkq326

DO - 10.1093/jac/dkq326

M3 - Article

C2 - 20817922

AN - SCOPUS:77957875432

VL - 65

SP - 2305

EP - 2318

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 11

M1 - dkq326

ER -

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this